Natural-dissolving scaffolds called Bioabsorbable Vascular Scaffold are utilised to treat coronary artery disease (CAD). These are the most recent advancements in metal stent technology, coated with a polymer that contains anti-proliferative medications like Sirolimus or Everolimus. In the human body, these biodegradable vascular scaffolds broke down. As a result, these stents eliminate the need for post-treatment procedures and stop the inflammation that causes thrombosis and stent restenosis.
Due to their long-term anticoagulation requirements and decreased host/device interaction, Bioabsorbable Vascular Scaffold are frequently favoured over permanent implants during percutaneous transluminal coronary angioplasty. While BVS have shown promise in clinical trials, there is still much research to be done to fully understand their safety and efficacy in real-world clinical practice. There are ongoing studies evaluating the long-term outcomes of BVS, as well as studies comparing different types of scaffolds to determine which are most effective in different patient populations.
